Latest Drug Addiction Treatment Act Stories
2014 - A Year of Many Significant Milestones, with More Expected for 2015, as BDSI Continues its Growth as an Integrated Specialty Pharmaceutical Company RALEIGH, N.C., March 16, 2015 /PRNewswire/
Data presented from largest combination buprenorphine/naloxone opioid dependence trial ever conducted in the U.S. MORRISTOWN, N.J., Dec. 6, 2014 /PRNewswire/ -- Orexo US, Inc.
BUNAVAIL(TM) (buprenorphine and naloxone) buccal film now available by prescription for the maintenance treatment of opioid dependence RALEIGH, N.C., Nov.
Complementary to BUNAVAIL(TM); Potential to Leverage Current Addiction Sales Force RALEIGH, N.C., Oct. 28, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc.
Helping eligible opioid dependent patients in need MORRISTOWN, N.J., Oct. 7, 2014 /PRNewswire/ -- As part of our ongoing commitment to addiction medicine, Orexo US, Inc.
95 of 180 Patients Enrolled; Additional Patients Screened, Awaiting Randomization PRINCETON, N.J., Sept.
September 4th ceremony celebrates 2014 accomplishments including FDA approval and anticipated commercial launch of BUNAVAIL RALEIGH, N.C., Sept.
BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3 RALEIGH, N.C., Aug.
First and Only FDA-Approved Buccal Film Formulation of Buprenorphine and Naloxone to Compete in the $1.7 Billion and Growing U.S.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.